The Effects of Nutritional Supplementation and Drug Abuse on HIV
Overview
The purpose of this trial is to determine whether supplementation with multivitamins and selenium will delay disease progression in HIV infected individuals in Botswana. The study will also assess how drug abuse modifies the effect of nutritional supplementation on HIV disease progression.
Full Title of Study: “HIV Disease, Drug Abuse, and Nutrient Therapy in Botswana”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Primary Purpose: Treatment
- Masking: Double (Participant, Investigator)
- Study Primary Completion Date: July 2010
Detailed Description
Botswana has the highest rates of HIV infection in the world. In addition, drug abuse has become an emerging problem in Botswana. Past research suggests that multivitamin and selenium supplementation slows the progression of HIV disease. The purpose of this trial is to evaluate the effectiveness of supplementation with multivitamins and selenium in HIV infected individuals in Botswana. This trial will last 2 years. Participants will be randomly assigned to 4 groups: a combination of multivitamins with selenium, multivitamins alone, selenium alone, or placebo.
Interventions
- Dietary Supplement: Multivitamins
- dietary supplement of multivitamins
- Dietary Supplement: Selenium
- dietary supplement of selenium only
- Other: Placebo
- placebo pill
Arms, Groups and Cohorts
- Placebo Comparator: 1
- Experimental: 2
- Multivitamins
- Experimental: 3
- Multivitamins with Selenium
- Experimental: 4
- Selenium
Clinical Trial Outcome Measures
Primary Measures
- HIV Disease Progression
- Time Frame: For at least 6 months
Secondary Measures
- Morbidity
- Time Frame: For at least 6 months
Participating in This Clinical Trial
Inclusion Criteria
- HIV infected – CD4 count greater than 350 cells/mm3 – Identified from the Infectious Disease Care Clinic – Body mass index greater than 18 for women and greater than 18.5 for men Exclusion Criteria:
- Current AIDS-defining condition – Currently participating in another clinical trial – Pregnant or intends to become pregnant during the study
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 90 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Florida International University
- Collaborator
- National Institute on Drug Abuse (NIDA)
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Marianna K. Baum, PhD, Principal Investigator, Florida International University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.